Axcella Announces Initiation of EMMPACT℠ Phase 2b Clinical Trial of AXA1125
Initial clinical sites activated and patient screening underway
Potential for AXA1125 to serve as a first-line therapy for patients with nonalcoholic steatohepatitis (NASH)
CAMBRIDGE, Mass. (BUSINESS WIRE) Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that it has activated initial clinical sites and begun patient screening for its EMMPACT Phase 2b clinical trial of AXA1125, the company’s multi-targeted oral product candidate for the treatment of NASH.
“NASH is the quintessential complex disease, involving the dysregulation of numerous biological pathways and impacting an enormous, heterogenous global population,” said Stephen A. Harrison, M.D., Medical Director of Pinnacle Clinical Research in San Antonio, TX, visi
Axcella Announces AXA1125's IND Clearance for the Treatment of NASH pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
Experienced biopharma leader to oversee research, candidate development, clinical and regulatory functions
CAMBRIDGE, Mass. (BUSINESS WIRE) Axcella (Nasdaq:AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced the appointment of Alison D. Schecter, M.D., as the company’s President of Research and Development. In this role, Dr. Schecter will oversee all of the company’s research, product candidate design, clinical and regulatory efforts. Additionally, Manu Chakravarthy, M.D., Ph.D., has decided to step down as the company’s Chief Medical Officer to pursue another opportunity.
Combination pack for two cancer drugs approved packagingdigest.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from packagingdigest.com Daily Mail and Mail on Sunday newspapers.
AXA1665 Phase 2 trial initiation planned for Q2
AXA1125 Phase 2b trial initiation planned for Q2
Company decides not to expand enrollment in AXA4010-001 following cohort 1 readout
Pipeline. | January 16, 2021